Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Real-world data supports tolvaptan use to slow kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD).

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

In some patients, ADPKD progresses to end-stage renal disease. Standard ADPKD treatment is managing symptoms and trying to slow disease progression. The lone therapeutic is tolvaptan, brand name ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...

Novartis Development president and chief medical officer Shreeram Aradhye stated: "With limited treatment options currently ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...